Study to Understand Why Some Adults With Acute Leukemia, Myelodysplastic Syndrome, or Myeloproliferative Neoplasms Do or Do Not Receive Allogeneic Stem Cell Transplants

What this Trial Is About

Researchers are conducting an observational study to understand the percentage of patients with acute leukemia, myelodysplastic syndrome MDS, and myeloproliferative neoplasms MPN who receive allogeneic hematopoietic stem cell transplantation HCT. The study aims to explore reasons why some patients undergo the transplant while others do not, including cases where patients choose not to have a transplant despite physician recommendations. This includes patients newly diagnosed, relapsed, or experiencing post-transplant relapse. Participants are grouped into three arms based on their diagnosis Arm A includes patients with acute leukemia Arm B includes patients with MDS and MPN meeting specific clinical criteria Arm C includes patients who relapse after their first transplant. The study follows patients throughout their treatment journey to identify barriers to proceeding with HCT when eligible. Assessments and laboratory tests are performed as part of standard care, including HLA allele typing. Throughout the study, participants are observed during their treatment and follow-up periods. Researchers collect data from lab tests, clinical evaluations, and patient histories to understand transplant eligibility and decisions. The main outcome measured is the number of patients who proceed to transplantation over a three-year period. The study runs until February 2027 and includes adults aged 18 to 80 years.

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia